We analysed gene-expression profiles in 15 surgical specimens of conventional, papillary, and chromophobe renal cell carcinomas (RCCs) using high-density oligonucleotide arrays. From about 12 000 genes targeted by the array, 67 were upregulated specifically in each histological type of RCC. The oncogene KIT was one of the genes whose expression was upregulated specifically in chromophobe RCCs. Immunohistochemical analysis demonstrated the KIT gene product on the cell membrane of chromophobe RCC in all cases, although it was not detected in conventional RCCs or non-neoplastic kidneys except for weak staining in the cytoplasm of renal tubules. These results suggest that each histological subtype of RCC has a unique gene-expression profile, and in particular indicates for the first time that KIT could be a useful marker for chromophobe RCC. As overexpression of KIT might be involved in tumor growth, KIT could be a new therapeutic target in this special type of RCC.
Introduction
In addition to the classification based on cell type (clear cell, granular cell, or sarcomatoid) and growth pattern (alveolar, papillary, cystic, or solid), the classification of renal cell carcinoma (RCC) into conventional RCC, papillary RCC, chromophobe RCC, collecting-duct carcinoma, and unclassified RCC has been established and widely applied (Kovacs et al., 1997; Storkel et al., 1997) . The latter classification is based on cytogenetic and morphological aspects. Conventional RCC accounts for 70-80% of renal tumors in surgical series and is genetically characterized by loss of chromosome 3p and von Hippel-Lindau (VHL) gene abnormality (Gnerra et al., 1994; Kenck et al., 1996) . Cells with clear cytoplasm are predominant in this tumor and the growth pattern is alveolar and cystic, although focal papillary architecture is frequently seen in the lesions. In papillary RCC, a papillary growth pattern with basophilic and/or eosinophilic cells predominates (Thoenes et al., 1986) , and genetically this type is characterized by trisomy of chromosomes 3q, 7, 12, 16, 17, and 20 and loss of the Y chromosome (Dijkhuizen et al., 1996) . Mutation in the MET oncogene correlates with tumorigenesis of hereditary and sporadic papillary RCC (Schmidt et al., , 1999 . Chromophobe RCC is composed of cells with pale or eosinophilic cytoplasm. Monosomy of multiple chromosomes (1, 2, 6, 10, 13, 17, and 21 ) is common in this tumor (Kovacs and Kovacs, 1992; Speicher et al., 1994) , although no genes for which mutation or loss of heterozygosity appears to be associated with tumorigenesis have been identified.
Expression profiling of a wide range of genes can provide an enormous amount of information about a tissue sample. The microarray is a useful tool for analysing the expression of a large number of genes at once, and the profiles can identify unexpected genes based on a new viewpoint. Two recent reports have profiled RCC using microarrays (Takahashi et al., 2001; Young et al., 2001) . Young et al. provided diagnostic molecular markers for distinguishing conventional RCC, chromophobe RCC, and oncocytoma. Takahashi et al. identified some genes for prognostic classification of conventional RCCs. Both of these studies revealed genes that were upregulated in conventional RCC but not in chromophobe RCC/oncocytoma (Young et al., 2001) or non-neoplastic kidney (Takahashi et al., 2001) . The aim of the present study was to clarify the expression patterns of a large number of genes in the three major types of RCC. Here we report the expression profiles of genes that were found to be upregulated in specific types of RCC, and the specific overexpression of KIT in chromophobe RCCs.
Results

Gene-expression profiling of RCC
Samples for expression profiling included 10 conventional RCCs, two papillary RCCs, three chromophobe RCCs, and their corresponding specimens of non-neoplastic kidney tissue. Conventional RCCs with focal papillary architecture were excluded from this study. Biotin-labeled cRNA was prepared from total RNA extracted from each sample, and hybridized to the high-density oligonucleotide array, HG-U95A (Affymetrix, Santa Clara, CA, USA). The scanned image of each array was processed by the Microarray Suite software package (Affymetrix) to normalize the total expression level in the tumor to the same level as that in each corresponding sample of non-neoplastic kidney.
To list the upregulated genes in each tumor sample, we picked genes from the data that matched the following criteria: (1) presence (i.e. unambiguously expressed in the sample) assessed by the software, (2) average difference of more than 1 000 (mean difference in signal intensity between perfect match and mismatch probe pairs), and (3) more than a threefold increase of average difference compared with that in the corresponding non-neoplastic kidney tissue. In each type of RCC, genes upregulated in all cases were extracted from the above list. Apolipoprotein C-I (APOC1) was overexpressed in almost all of the RCCs examined, platelet-derived endothelial cell growth factor 1 (ECGF1) and enolase 2 (ENO2) were overexpressed in both conventional and papillary RCCs, and epidermal growth factor receptor (EGFR), von Willebrand factor (VWF), and caveolins (CAV1 and CAV2) were overexpressed in both conventional and chromophobe RCCs. Finally, we selected 67 genes that were upregulated specifically in each type of RCC (Table 1) . Downregulation of genes such as secreted frizzledrelated protein 1 (SFRP1), sodium-potassium-chloride transporter 2 (SLC12A1), potassium inwardly rectifying channel, subfamily J, member 1 (KCNJ1), serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5 (SERPINA5), kininogen (KNG), uromodulin (UMOD), aquaporin 3 (AQP3), and metallothioneins (MT1A, MT1E, MT1F, MT1G, MT1H, and MT1H) was common in all RCCs examined upon comparison with those in the corresponding samples of non-neoplastic kidney tissue.
Mutations and loss of heterozygosity of the VHL gene are often seen in conventional RCCs. Since VHL is involved in the degradation of hypoxia inducible factor 1 alpha (HIF1A), it was expected that target genes of HIF1 (HIF1A/HIF1B complex) would be upregulated in conventional RCCs. Among such genes, those for vascular endothelial growth factor (VEGF) and insulin-like growth factor binding protein 3 (IGFBP3) were upregulated in all conventional RCCs (Table 1 ). The carbonic anhydrase IX (CA9) gene was upregulated in all conventional RCCs plus one of the two papillary RCCs and the serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 (SERPINE1) gene was upregulated in nine of the 10 conventional RCCs; therefore, these two genes were eliminated from the list. As shown in Figure 1 , overexpression of VEGF and SERPINE1 in conventional RCCs was confirmed by RT-PCR.
Expression of KIT in RCC
Gene-expression profiles indicated that KIT was upregulated specifically in chromophobe RCCs, and this was supported by the results of RT-PCR (Figure 1) . Sections of chromophobe RCCs in three cases analysed for expression profiling and one additional case were subjected to immunohistochemical analysis using the anti-KIT antibody. All four cases examined demonstrated strong expression of KIT on the cell membrane of chromophobe RCC cells (Figure 2a-d) . In nonneoplastic kidney tissue, weak KIT expression was detected in the cytoplasm of renal tubules (Figure 2e ).
Since the KIT gene encodes the transmembrane receptor for KIT ligand (KITLG, also known as mast 
Discussion
The gene-expression profiles determined in the present study revealed differences in the expression patterns of some growth factor receptors among conventional, papillary, and chromophobe RCCs. The oncogene KIT was shown for the first time by gene-expression profiling to be one of the genes characterizing chromophobe RCC. It has been reported that other growth factors such as EGFR (Freeman et al., 1989; Ishikawa et al., 1990) and hepatocyte growth factor receptor MET (Natali et al., 1996; Nakopoulou et al., 1997) are overexpressed in RCCs. The profiles obtained in this study also showed upregulation of EGFR and MET in RCCs, although they were not recognized as genes specifying the subtypes of RCC. Specific overexpression of the KIT gene in chromophobe RCCs was confirmed by RT-PCR, and immunohistochemical analyses showed that KIT was localized to the cell membrane of chromophobe RCC cells. Although mutations in the VHL and MET genes are known to be involved in the tumorigenesis of conventional RCCs and papillary RCCs, respectively, no oncogenes or tumor-suppressor genes correlated with the tumorigenesis of chromophobe RCC have been reported. Therefore, our present data are expected to clarify the nature of tumorigenesis of chromophobe RCC. Overexpression and mutation of the KIT oncogene are known in several kinds of cancers. Constitutively activated mutations of KIT play a role in the tumorigenesis of mast cell leukemia (Furitsu et al., 1993) and gastrointestinal stromal tumor (GIST) Nishida et al., 1998) . KIT mutations in GISTs occur mainly in the region between the transmembrane and tyrosine kinase domains (Rubin et al., 2001) . Sequencing analysis of the KIT gene in the three chromophobe RCCs demonstrated no mutation in the region. Overexpression of wild-type KIT and coexpression of KITLG are indicated to be involved in the transformation of NIH3T3 fibroblasts (Caruana et al., 1998) and the tumorigenesis of small cell lung cancer (Hibi et al., 1991) . The expression of KITLG in not only chromophobe RCCs but also non-neoplastic kidney tissue was confirmed by RT-PCR, suggesting that the KIT signal pathway in tumor cells of chromophobe RCC is activated in an autocrine/paracrine manner. It has been reported that KIT could be a good therapeutic target for the treatment of several cancer types. The KIT tyrosine kinase inhibitor STI571 suppresses the growth of small cell lung cancer cells (Krystal et al., 2000; Wang . Blocking of KIT activity could also inhibit tumor growth in chromophobe RCCs.
Two previous studies on the expression profiling of RCCs (Takahashi et al., 2001; Young et al., 2001) , together with ours, have listed many identical genes that are overexpressed in RCC in a type-specific manner. One of the characteristics of conventional RCC is upregulation of genes that are inducible by hypoxia. Hypoxia is a common phenomenon in most solid tumors and leads to the expression of hypoxia-inducible factor 1 alpha subunit (HIF1A) regulated by VHLmediated ubiquitination under nonhypoxic conditions (Cockman et al., 2000; Kamura et al., 2000; Tanimoto et al., 2000) . Some genes have been reported to be HIF1 (HIF1A/HIF1B complex) target genes, such as VEGF, SERPINE1, IGFBP3, and CA9 (Semenza, 2000) , and all four were found to be upregulated in almost all the conventional RCCs we examined. Consequently, conventional RCC shows features related to hypoxia in its gene-expression profile. Takahashi et al. (2001) also demonstrated overexpression of VEGF and IGFBP3 in conventional RCCs by gene-expression profiling using microarrays. Loss of function of VHL by mutation, deletion, and silencing by methylation of the promoter is frequently seen in familial and sporadic conventional RCCs, leading to the overexpression of some genes in conventional RCCs induced by HIF1A stabilization (Cockman et al., 2000) . Hypervascularization occurs in almost all conventional RCCs, unlike papillary and chromophobe RCCs. This difference of angiogenesis may be associated with the expression level of an angiogenesis factor, VEGF, and may be responsible for the differences in histological structure to some extent.
In conclusion, we have demonstrated that KIT is overexpressed in chromophobe RCCs. KIT may be a useful tumor marker and also a therapeutic target for treatment of chromophobe RCCs.
Materials and methods
Surgical specimens
All tissue samples of RCC and the corresponding nonneoplastic kidney were obtained from patients who underwent nephrectomy at the National Cancer Center, Tokyo, Japan. The surgical specimens were cut into small pieces and snapfrozen in liquid nitrogen.
Total RNA extraction
Each sample was homogenized in a FastRNA tube (Qbiogene Inc., Carlsbad, CA, USA) containing 600 ml of TRIzol (Invitrogen, Carlsbad, CA, USA) using a FastPrep FP120 homogenizer (Qbiogene Inc.). After the homogenization step, total RNA was extracted according to the protocol of Invitrogen. The quality of each RNA was checked by electrophoresis, and only samples of intact RNA were used for further analysis.
GeneChip analysis
Biotin-labeled cRNA was synthesized from 5 mg of total RNA derived from each sample using a Superscript Choice System (Invitrogen) and BioArray High Yield RNA Transcript Labeling Kit (Enzo Diagnostics, Farmingdale, NY, USA) according to the manufacturers' instructions. Hybridization of each cRNA to the probe array, HG-U95Av2 (Affymetrix), and detection of the signals were performed as instructed by the manufacturer. Using the Microarray Suite 4.0 software package (Affymetrix), the scanned image was transformed for each probe set into average differences representing the mean difference of signal intensity between the match and mismatch probe pairs, and thus the expression level of the target gene. The fold change of each probe set presenting the ratio of the gene-expression level in the tumor relative to that in the non-neoplastic kidney from the same patient was calculated using Microarray Suite 4.0 and compared among the tumor samples using the Microsoft EXCEL 2000 software package.
RT-PCR
Oligo-dT-primed reverse transcripts derived from 50 ng of total RNA were amplified by PCR with ExTaq polymerase (Takara Shuzo, Kyoto, Japan) using gene-specific primer sets. 
Immunohistochemical analysis
The specimens of conventional and chromophobe RCCs and non-neoplastic kidney tissue were fixed in 10% formalin, embedded in paraffin, and sliced into sections of 3 mm thickness. The sections were deparaffinized with graded ethanol and xylene, immersed in methanol containing 0.3% H 2 O 2 for 30 min, and rinsed with phosphate-buffered saline (pH 7.4). After autoclaving, the sections were incubated with anti-KIT antibody (DAKO, Glostrup, Denmark) at a dilution of 1 : 50 overnight at 41C. The sections were incubated with biotinylated antibody against rabbit IgG (Vector Laboratories, Burlingame, CA, USA) at a dilution of 1 : 200 for 30 min at room temperature and then with the Vectastain ABC reagent (Vector Laboratories) for 30 min. To visualize the reaction, the sections were immersed in 0.05% diaminobenzidine tetrahydrochloride solution containing 0.01% H 2 O 2 , and counterstained with hematoxylin.
